Top

Published in:

01-02-2019 | Original Article

Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project

Authors: Marina E. Cazzaniga, E. Ciruelos, A. Fabi, J. Garcia-Saenz, H. Lindman, D. Mavroudis, C. Schem, G. Steger, E. Timotheadou, K. Zaman, V. Torri, on behalf of the MACBETH Group

Published in: Cancer Chemotherapy and Pharmacology | Issue 2/2019

Abstract

Introduction

Despite the large use of nab-paclitaxel as a treatment option in metastatic breast cancer (MBC) across different countries, no definitive data are available in particular clinical situations.

Areas covered

Efficacy, safety and schedule issues concerning available literature on nab-paclitaxel in advanced breast cancer and in specific subgroups of patients have been discussed and voted during an International Expert Meeting. Ten expert specialists in oncology, with extensive clinical experience on Nab-P and publications in the field of MBC have been identified. Six scientific areas of interest have been covered, generating 13 specific Statements for Nab-P, after literature review. For efficacy issues, a summary of research quality was performed adopting the GRADE algorithm for evidence scoring. The panel members were invited to express their opinion on the statements, in case of disagreement all the controversial opinions and the relative motivations have been made public.

Expert opinion

Consensus was reached in 30.8% of the Nab-P statements, mainly those regarding safety issues, whereas ones regarding efficacy and schedule still remain controversial areas, requiring further data originated by the literature.

Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur J Cancer Oxf Engl 1990 37(13):1590–1598

Nyman DW et al (2005) Phase I and pharmacokinetics trial of ABI-007, a novel nanoparticle formulation of paclitaxel in patients with advanced nonhematologic malignancies. J Clin Oncol 23(31):7785–7793CrossRef

Gradishar WJ et al (2005) Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 23(31):7794–7803CrossRef

Gradishar WJ et al (2009) Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 27(22):3611–3619CrossRef

Bernardo A et al (Oct. 2017) Nab-paclitaxel in advanced HER2-negative breast cancer patients: efficacy and safety beyond clinical trials. Clin Breast Cancer 17(6):433–440CrossRef

Palumbo R et al (2015) Nanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life. Drug Des Dev Ther 9:2189–2199CrossRef

Fabi A et al (2015) Prospective study on nanoparticle albumin-bound paclitaxel in advanced breast cancer: clinical results and biological observations in taxane-pretreated patients. Drug Des Dev Ther 9:6177–6183CrossRef

Cardoso F et al (2012) 1st International consensus guidelines for advanced breast cancer (ABC 1). Breast Edinb Scotl 21(3):242–252CrossRef

“GRADE handbook (2018) [Online]. http://gdt.guidelinedevelopment.org/app/handbook/handbook.html. Accessed 01 Mar 2018

10.

Sharma P et al (2017) Efficacy of neoadjuvant carboplatin plus docetaxel in triple negative breast cancer: combined analysis of two cohorts. Clin Cancer Res 23(3):649–657CrossRef

11.

Miles DW, Diéras V, Cortés J, Duenne A-A, Yi J, O’Shaughnessy J (2013) First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients. Ann Oncol 24(11):2773–2780CrossRef

12.

Blum JL et al (2007) Phase II study of weekly albumin-bound paclitaxel for patients with metastatic breast cancer heavily pretreated with taxanes. Clin Breast Cancer 7(11):850–856CrossRef

13.

Forero-Torres A et al (2015) TBCRC 019: a phase II trial of nanoparticle albumin-bound paclitaxel with or without the anti-death receptor 5 monoclonal antibody tigatuzumab in patients with triple-negative breast cancer. Clin Cancer Res 21(12):2722–2729PubMedCentralCrossRef

14.

Kassam F et al (2009) Survival outcomes for patients with metastatic triple-negative breast cancer: implications for clinical practice and trial design. Clin Breast Cancer 9(1):29–33CrossRef

15.

Untch M et al (2016) Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial. Lancet Oncol 17(3):345–356CrossRef

16.

Hammond MEH et al (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch Pathol Lab Med 134(7):e48–e72PubMed

17.

Onitilo AA, Engel JM, Greenlee RT, Mukesh BN (2009) Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 7(1–2):4–13PubMedCentralCrossRef

18.

Cardoso F et al (2017) 3rd ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3). Ann Oncol 28(12):3111PubMedCentralCrossRef

19.

Lobbezoo DJA et al (2016) In real life, one-quarter of patients with hormone receptor-positive metastatic breast cancer receive chemotherapy as initial palliative therapy: a study of the Southeast Netherlands Breast Cancer Consortium. Ann Oncol 27(2):256–262CrossRef

20.

Robertson JFR et al (2016) Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet Lond Engl 388(10063):2997–3005CrossRef

21.

Hortobagyi GN et al (03 2016) Ribociclib as first-line therapy for HR-positive, advanced breast cancer. N Engl J Med 375(18):1738–1748CrossRef

22.

Finn RS et al (2016) Palbociclib and letrozole in advanced breast cancer. N Engl J Med 375(20):1925–1936CrossRef

23.

Goetz MP et al (2017) MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer. J Clin Oncol 35(32):3638–3646CrossRef

24.

Turner NC et al (2015) Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med 373(3):209–219CrossRef

25.

Sledge GW et al (2017) MONARCH 2: abemaciclib in combination With fulvestrant in women with HR+/HER2− advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 35(25):2875–2884CrossRef

26.

Piccart M et al (2014) Everolimus plus exemestane for hormone-receptor-positive, human epidermal growth factor receptor-2-negative advanced breast cancer: overall survival results from BOLERO-2†. Ann Oncol 25(12):2357–2362PubMedCentralCrossRef

27.

NCCN—Evidence-Based Cancer Guidelines, Oncology Drug Compendium, Oncology Continuing Medical Education (2018). https://www.nccn.org/. Accessed 01 Mar 2018

28.

Johnson RH, Chien FL, Bleyer A (2013) Incidence of breast cancer with distant involvement among women in the United States, 1976 to 2009. JAMA 309(8):800–805CrossRef

29.

Solomayer EF, Diel IJ, Meyberg GC, Gollan C, Bastert G (2000) Metastatic breast cancer: clinical course, prognosis and therapy related to the first site of metastasis. Breast Cancer Res Treat 59(3):271–278CrossRef

30.

Howell A, Robertson JFR, Vergote I (2003) A review of the efficacy of anastrozole in postmenopausal women with advanced breast cancer with visceral metastases. Breast Cancer Res Treat 82(3):215–222CrossRef

31.

Wilcken N, Hornbuckle J, Ghersi D Chemotherapy alone versus endocrine therapy alone for metastatic breast cancer. Cochrane Database Syst Rev 2:CD002747, 2003

32.

Bachelot T et al (Aug. 2012) Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study. J Clin Oncol 30(22):2718–2724CrossRef

33.

Raphael J, Helou J, Pritchard KI, Naimark DM (2017) Palbociclib in hormone receptor positive advanced breast cancer: a cost-utility analysis. Eur J Cancer Oxf Engl 1990 85:146–154

34.

Rugo HS et al (Jul. 2015) Randomized phase III trial of paclitaxel once per week compared with nanoparticle albumin-bound nab-paclitaxel once per week or ixabepilone with bevacizumab as first-line chemotherapy for locally recurrent or metastatic breast cancer: CALGB 40502/NCCTG N063H (alliance). J Clin Oncol Off J Am Soc Clin Oncol 33(21):2361–2369CrossRef

35.

Biganzoli L et al (Apr. 2012) Management of elderly patients with breast cancer: updated recommendations of the International Society of Geriatric Oncology (SIOG) and European Society of Breast Cancer Specialists (EUSOMA). Lancet Oncol 13(4):e148–e160CrossRef

36.

Crivellari D et al (2007) Breast cancer in the elderly. J Clin Oncol Off J Am Soc Clin Oncol 25(14):1882–1890CrossRef

37.

Biganzoli L, Aapro M, Loibl S, Wildiers H, Brain E (2016) Taxanes in the treatment of breast cancer: have we better defined their role in older patients? A position paper from a SIOG task force. Cancer Treat Rev 43:19–26CrossRef

38.

Aapro M, Tjulandin S, Bhar P, Gradishar W (2011) Weekly nab-paclitaxel is safe and effective in ≥ 65 years old patients with metastatic breast cancer: a post-hoc analysis. Breast Edinb Scotl 20(5):468–474CrossRef

39.

Ibrahim NK et al (2005) Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer. J Clin Oncol 23(25):6019–6026CrossRef

40.

Liang C et al (2015) The treatment patterns, efficacy, and safety of nab^®-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. BMC Cancer 15:1019PubMedCentralCrossRef

41.

Cold S, Düring M, Ewertz M, Knoop A, Møller S (2005) Does timing of adjuvant chemotherapy influence the prognosis after early breast cancer? Results of the Danish breast cancer cooperative group (DBCG). Br J Cancer 93(6):627–632PubMedCentralCrossRef

Title: Metastatic or locally advanced breast cancer patients: towards an expert consensus on nab-paclitaxel treatment in HER2-negative tumours—the MACBETH project
Authors: Marina E. Cazzaniga
E. Ciruelos
A. Fabi
J. Garcia-Saenz
H. Lindman
D. Mavroudis
C. Schem
G. Steger
E. Timotheadou
K. Zaman
V. Torri
on behalf of the MACBETH Group
Publication date: 01-02-2019
Publisher: Springer Berlin Heidelberg
Published in: Cancer Chemotherapy and Pharmacology / Issue 2/2019
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI: https://doi.org/10.1007/s00280-018-3717-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Introduction

Areas covered

Expert opinion

Please log in to get access to this content

Other articles of this Issue 2/2019

Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study

6-MOMIPP, a novel brain-penetrant anti-mitotic indolyl-chalcone, inhibits glioblastoma growth and viability

A prospective study of a simple algorithm to individually dose high-dose methotrexate for children with leukemia at risk for methotrexate toxicities

Prevalence of TPMT, ITPA and NUDT 15 genetic polymorphisms and their relation to 6MP toxicity in north Indian children with acute lymphoblastic leukemia

Toll-like receptor/interleukin-1 domain innate immune signalling pathway genetic variants are candidate predictors for severe gastrointestinal toxicity risk following 5-fluorouracil-based chemotherapy

Population pharmacokinetic and covariate analyses of intravenous trastuzumab (Herceptin®), a HER2-targeted monoclonal antibody, in patients with a variety of solid tumors

Keynote webinar | Spotlight on antibody–drug conjugates in cancer